503 related articles for article (PubMed ID: 23787449)
1. Choroidal thickness after treatment for myopic
choroidal neovascularization.
Farinha CL; Baltar AS; Nunes SG; Franqueira NF; Figueira JP; Pires IA; Cachulo ML; Silva RM
Eur J Ophthalmol; 2013; 23(6):887-98. PubMed ID: 23787449
[TBL] [Abstract][Full Text] [Related]
2. Progression of myopic maculopathy after treatment of choroidal neovascularization.
Farinha CL; Baltar AS; Nunes SG; Figueira JP; Pires IA; Cachulo ML; Silva RM
Ophthalmologica; 2014; 231(4):211-20. PubMed ID: 24662778
[TBL] [Abstract][Full Text] [Related]
3. Long-term functional and morphologic retinal changes after ranibizumab and photodynamic therapy in myopic choroidal neovascularization.
Parravano M; Ricci F; Oddone F; Missiroli F; De Felici C; Varano M
Retina; 2014 Oct; 34(10):2053-62. PubMed ID: 24946101
[TBL] [Abstract][Full Text] [Related]
4. Comparison of visual outcome and regression pattern of myopic choroidal neovascularization after intravitreal bevacizumab or after photodynamic therapy.
Hayashi K; Ohno-Matsui K; Teramukai S; Shimada N; Moriyama M; Hayashi W; Yoshida T; Tokoro T; Mochizuki M
Am J Ophthalmol; 2009 Sep; 148(3):396-408. PubMed ID: 19427991
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
6. Long-term variable outcome of myopic choroidal neovascularization treated with ranibizumab.
Cohen SY; Nghiem-Buffet S; Grenet T; Dubois L; Ayrault S; Fajnkuchen F; Delahaye-Mazza C; Quentel G; Tadayoni R
Jpn J Ophthalmol; 2015 Jan; 59(1):36-42. PubMed ID: 25416566
[TBL] [Abstract][Full Text] [Related]
7. Subfoveal Choroidal Thickness Changes Following Anti-Vascular Endothelial Growth Factor Therapy in Myopic Choroidal Neovascularization.
Ahn SJ; Park KH; Woo SJ
Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5794-800. PubMed ID: 26325418
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors of eyes with naïve subfoveal myopic choroidal neovascularization after intravitreal bevacizumab.
Yang HS; Kim JG; Kim JT; Joe SG
Am J Ophthalmol; 2013 Dec; 156(6):1201-1210.e2. PubMed ID: 24075429
[TBL] [Abstract][Full Text] [Related]
9. FIVE-YEAR OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN PATIENTS WITH PATHOLOGIC MYOPIA.
Onishi Y; Yokoi T; Kasahara K; Yoshida T; Nagaoka N; Shinohara K; Kaneko Y; Suga M; Uramoto K; Ohno-Tanaka A; Ohno-Matsui K
Retina; 2019 Jul; 39(7):1289-1298. PubMed ID: 29746414
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal ranibizumab versus bevacizumab for treatment of myopic choroidal neovascularization.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Cascavilla ML; Bandello F
Retina; 2012 Sep; 32(8):1539-46. PubMed ID: 22922846
[TBL] [Abstract][Full Text] [Related]
11. Comparison between anti-vascular endothelial growth factor therapy and photodynamic therapy for myopic choroidal neovascularization.
Matsuo M; Honda S; Matsumiya W; Kusuhara S; Tsukahara Y; Negi A
Eur J Ophthalmol; 2012; 22(2):210-5. PubMed ID: 21534251
[TBL] [Abstract][Full Text] [Related]
12. Intravitreal ranibizumab therapy versus photodynamic therapy for idiopathic choroidal neovascularization: a comparative study on visual acuity, retinal and choroidal thickness.
Shi X; Wei W; Zhang C
Chin Med J (Engl); 2014; 127(12):2279-85. PubMed ID: 24931242
[TBL] [Abstract][Full Text] [Related]
13. Reduced-fluence verteporfin photodynamic therapy plus ranibizumab for choroidal neovascularization in pathologic myopia.
Rinaldi M; Semeraro F; Chiosi F; Russo A; Romano MR; Savastano MC; dell'Omo R; Costagliola C
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):529-539. PubMed ID: 27680013
[TBL] [Abstract][Full Text] [Related]
14. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
15. Myopic choroidal neovascularization treated by intravitreal bevacizumab: comparison of two different initial doses.
Ruiz-Moreno JM; Montero JA; Amat-Peral P
Graefes Arch Clin Exp Ophthalmol; 2011 Apr; 249(4):595-9. PubMed ID: 21234588
[TBL] [Abstract][Full Text] [Related]
16. Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization.
Yoon JU; Byun YJ; Koh HJ
Retina; 2010 Mar; 30(3):418-24. PubMed ID: 20094012
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor gene and the response to anti-vascular endothelial growth factor treatment for choroidal neovascularization in high myopia.
Miyake M; Yamashiro K; Akagi-Kurashige Y; Kumagai K; Nakata I; Nakanishi H; Oishi A; Tsujikawa A; Yamada R; Matsuda F; Yoshimura N
Ophthalmology; 2014 Jan; 121(1):225-233. PubMed ID: 23953100
[TBL] [Abstract][Full Text] [Related]
18. CLINICAL OUTCOMES OF INTRAVITREAL BEVACIZUMAB VERSUS PHOTODYNAMIC THERAPY WITH OR WITHOUT BEVACIZUMAB FOR MYOPIC CHOROIDAL NEOVASCULARIZATION: A 7-Year Follow-up Study.
Kang EC; Seo JG; Kim BR; Koh HJ
Retina; 2017 Sep; 37(9):1775-1783. PubMed ID: 27997511
[TBL] [Abstract][Full Text] [Related]
19. Classification of early dry-type myopic maculopathy with macular choroidal thickness.
Wang NK; Lai CC; Chu HY; Chen YP; Chen KJ; Wu WC; Yeh LK; Chuang LH; Chen TL
Am J Ophthalmol; 2012 Apr; 153(4):669-77, 677.e1-2. PubMed ID: 22071232
[TBL] [Abstract][Full Text] [Related]
20. The relationship between retinal and choroidal thickness and visual acuity in highly myopic eyes.
Flores-Moreno I; Ruiz-Medrano J; Duker JS; Ruiz-Moreno JM
Br J Ophthalmol; 2013 Aug; 97(8):1010-3. PubMed ID: 23766433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
